Passa al contenuto
Merck
Tutte le immagini(2)

Documenti fondamentali

Visualizza tutta la documentazione

SAB4200772

Sigma-Aldrich

Anti-BRAF (V600E) antibody produced in rabbit

enhanced validation

affinity isolated antibody

Sinonimo/i:

Anti-Proto-oncogene B-Raf, p94, Anti-Serine/threonine-protein kinase B-raf, Anti-v-Raf murine sarcoma viral oncogene homolog B1

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(2)

About This Item

Codice UNSPSC:
12352203
NACRES:
NA.44

Origine biologica

rabbit

Livello qualitativo

200

Forma dell’anticorpo

affinity isolated antibody

Tipo di anticorpo

primary antibodies

Clone

polyclonal

Stato

buffered aqueous solution

PM

~95 kDa

Reattività contro le specie

human

Convalida avanzata

recombinant expression
Learn more about Antibody Enhanced Validation

Concentrazione

~1 mg/mL

tecniche

immunoblotting: 2-4 μg/mL using extract of human HEK-293T cells over-expressing BRAF mutant (V600E) protein

N° accesso UniProt

P15056

Condizioni di spedizione

dry ice

Temperatura di conservazione

−20°C

modifica post-traduzionali bersaglio

unmodified

Informazioni sul gene

human ... BRAF(673)

Descrizione generale

B-Raf proto-oncogene serine/threonine-protein kinase (BRAF), also known as Serine/threonine-protein kinase B-raf, Proto-oncogene B-Raf, p94, v-Raf murine sarcoma viral oncogene homolog B1, is a member of the RAF family. BRAF is one of the key factors in mitogen-activated protein kinase (MAPK) signaling pathway, which is activated by members of the Ras family upon growth factor-induced stimulation. BRAF controls and regulates numerous essential cellular mechanisms including cell proliferation, differentiation, development, survival, apoptosis and secretion.1-2 In contrast to the majority of oncogenic fusion kinases such as ALK, ROS1, NTRK1 and RET that are receptor tyrosine kinases, BRAF encodes a non-receptor serine/threonine kinase, placing its normal protein localization within the cytoplasm rather than associated with the plasma membrane.3
BRAF is mutated at a high frequency in several cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, nonsmall cell lung carcinoma, and adenocarcinoma of lung.

Specificità

Anti-BRAF (V600E) recognizes V600E mutated human BRAF protein. The antibody may be used in various immunochemical techniques including Immunoblotting.

Immunogeno

Synthetic peptide from the C-terminal region of human BRAF protein, conjugated to KLH

Applicazioni

Immunoblotting: a working concentration of 2-4 g/mL is recommended using extract of human HEK-293T cells over-expressing BRAF mutant (V600E) protein.

Stato fisico

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide

Non trovi il prodotto giusto?  

Prova il nostro Motore di ricerca dei prodotti.

Codice della classe di stoccaggio

10 - Combustible liquids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
077M4858V
51170502

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Nourah Mohammad Obaid et al.
International journal of molecular sciences, 18(3) (2017-03-12)
The development of resistance to previously effective treatments has been a challenge for health care providers and a fear for patients undergoing cancer therapy. This is an unfortunately frequent occurrence for patients undergoing targeted therapy for tumours harboring the activating
Roland Houben et al.
Journal of carcinogenesis, 3, 6-6 (2004-03-30)
Genes of the Raf family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Recently, it was shown that activating mutations of BRaf are found with high frequency in human melanomas. The Ras family member
Nicolas Stransky et al.
Nature communications, 5, 4846-4846 (2014-09-11)
Human cancer genomes harbour a variety of alterations leading to the deregulation of key pathways in tumour cells. The genomic characterization of tumours has uncovered numerous genes recurrently mutated, deleted or amplified, but gene fusions have not been characterized as
Alexandra Thiel et al.
Frontiers in oncology, 3, 281-281 (2013-12-04)
Different genetic aberrations of BRAF have been reported in various malignancies. BRAF is member of the RAS/RAF/MEK/ERK pathway and constitutive activity of this pathway can lead to increased cellular growth, invasion, and metastasis. The most common activating BRAF mutation in
Sara C Shalin
Laboratory investigation; a journal of technical methods and pathology, 97(2), 158-165 (2016-11-29)
Translocations resulting in a kinase fusion are well reported in many tumor types and indeed can be defining, particularly in the case of hematopoietic malignancies. The recent reports of multiple protein kinase fusions within melanocytic neoplasms, particularly in those with
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.